Clinical Trial Update: ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 trial evaluating ProAgio in combination with Gemcitabine for metastatic triple-negative breast cancer, with patient recruitment currently ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• ProAgio

Snippet

Sponsor: ProDa BioTech, LLC | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING